BMS Forgoes Thalassemia Label Expansion Revenues For Rebozyl

The firm was unable to respond to the US FDA’s questions on Reblozyl’s risk-benefit profile in an expanded beta-thalassemia setting and will now focus label expansion efforts elsewhere.